Dr. Mary Claire Haver's Women's HRT Protocol: What It Would Cost a Non-Celebrity

Who Is Dr. Mary Claire Haver and Why Does Her Regimen Matter?

Dr. Mary Claire Haver is a board-certified ob-gyn, a clinical associate professor, and the creator of The Galveston Diet and The Pause Life platform, which reaches millions of women through Instagram, TikTok, and podcast appearances. She sits at the intersection of practicing clinician and public health communicator, which makes her unusual: she openly discusses her own prescriptions in clinical detail rather than offering vague wellness advice.

Her transparency has real consequences for how women think about HRT. When a credentialed physician describes her exact medications, dosing philosophy, and rationale on a public platform, that information shapes patient expectations, search behavior, and telehealth demand. Understanding what she actually takes, and why, is therefore a legitimate clinical question.

What Dr. Haver Has Said Publicly About Her Own HRT

In multiple podcast interviews and social media posts between 2022 and 2024, Dr. Haver has described using a combination of transdermal estradiol, oral micronized progesterone (for uterine protection), and low-dose testosterone. She has framed testosterone as addressing libido, mood, energy, and cognitive clarity in perimenopause and menopause.

She has stated, in substance: that she uses the lowest effective dose of each hormone, that she prefers transdermal estradiol over oral estrogen because it avoids first-pass liver metabolism and carries a lower venous-thromboembolism risk, and that she views micronized progesterone as safer than synthetic progestins for breast tissue. These positions align with current evidence and guideline language, as detailed below.

Why Transdermal Over Oral Estrogen?

The preference for transdermal estradiol over oral conjugated equine estrogen has a clear mechanistic basis. Oral estrogens undergo first-pass hepatic metabolism, which raises sex-hormone-binding globulin, triglycerides, and C-reactive protein. Transdermal delivery bypasses this pathway entirely.

A 2020 observational analysis published in the BMJ (N=approximately 80,000 women) found that oral estrogen-only therapy was associated with a higher risk of venous thromboembolism compared with transdermal estradiol. [1] The 2022 Menopause Society (formerly NAMS) Position Statement states: "Transdermal estradiol is preferred for women with cardiovascular risk factors or elevated thrombotic risk." [2]

The Three-Drug Protocol: Clinical Breakdown

Dr. Haver's publicly described regimen maps to three distinct pharmacological categories. Each has a distinct evidence base, a distinct FDA status, and a distinct cost structure.

Component 1: Transdermal Estradiol

Transdermal estradiol is the backbone of virtually every evidence-based postmenopausal HRT regimen. It controls vasomotor symptoms (hot flashes, night sweats), protects bone mineral density, and supports urogenital tissue.

The Women's Health Initiative Memory Study and subsequent re-analyses established that timing of initiation matters enormously: women who begin HRT within 10 years of menopause or before age 60 see cardiovascular and cognitive benefits rather than the harms observed in older initiators. [3] The "timing hypothesis" is now endorsed by the Endocrine Society and the Menopause Society alike. [2][4]

Approved formulations and 2024 cash prices (GoodRx, major chain pharmacies):

| Formulation | Brand Example | Typical Monthly Cash Price | |---|---|---| | Patch (twice weekly) 0.05 mg/day | Climara, Vivelle-Dot | $30, $55 | | Gel 0.06% (EstroGel) | EstroGel | $60, $90 | | Spray (Evamist) | Evamist | $90, $140 | | Generic patch 0.05 mg/day | Various | $20, $40 |

For most women, a generic estradiol patch is the most cost-effective entry point. The 0.05 mg/day twice-weekly patch is the starting dose in most clinical protocols; Dr. Haver has referenced using patches in several podcast discussions.

Component 2: Oral Micronized Progesterone

Any woman with an intact uterus who takes systemic estrogen requires progestogen to prevent endometrial hyperplasia and adenocarcinoma. [2] Micronized progesterone (Prometrium) is bioidentical, meaning it is chemically identical to the progesterone the ovary produces. Synthetic progestins (medroxyprogesterone acetate, norethindrone) carry a modestly higher breast cancer signal in observational data, though absolute risk differences are small.

The E3N cohort study (N=80,377 French women, 8-year follow-up) found that estrogen combined with micronized progesterone was not associated with increased breast cancer risk, whereas estrogen combined with synthetic progestins was associated with a statistically significant increase. [5] These data drove a shift in European and then American prescribing toward micronized progesterone.

Prometrium 200 mg taken orally at bedtime for 12 days per cycle (cyclic use) or 100 mg nightly (continuous use) is the standard dosing. Cash price for 30 capsules of 200 mg Prometrium runs $55, $70 at retail; the generic micronized progesterone is $25, $45 for the same quantity.

Component 3: Low-Dose Testosterone (Off-Label)

This is the component that draws the most clinical debate and the most patient questions. The FDA has not approved any testosterone product for women in the United States. Prescribing testosterone for female hypoactive sexual desire disorder, fatigue, or cognitive symptoms is therefore off-label, though it is common in menopause-specialist practice.

The 2019 Global Consensus Position Statement on Testosterone for Women, published in the Journal of Clinical Endocrinology and Metabolism, states: "There is a moderate quality of evidence that testosterone improves sexual function in postmenopausal women." The statement was endorsed by the Endocrine Society and the British Society for Sexual Medicine. [4]

Typical doses for women are 5 to 10% of the male dose: 0.5 to 2 mg/day via cream or gel. Because no FDA-approved female formulation exists, women either use compounded testosterone cream (custom-made at a compounding pharmacy) or use a small fraction of a male product such as AndroGel 1.62%, with the dose adjusted accordingly. The compounded route is more common in telehealth menopause practices.

Compounded testosterone cream (typically 1 to 2 mg/0.1 mL applied to inner arm or labia minora daily) costs $30, $80 per month at compounding pharmacies, depending on concentration and quantity.

What the Full Protocol Costs Without Insurance

Most commercial insurance plans cover FDA-approved HRT poorly, and Medicare Part D coverage varies by plan. Here is a realistic cost model for a non-celebrity woman in 2024 paying cash or using GoodRx.

HealthRX Cost-Tier Framework: Dr. Haver-Style Three-Drug HRT Protocol

| Tier | Estradiol Option | Progesterone Option | Testosterone Option | Est. Monthly Total | |---|---|---|---|---| | Budget | Generic patch $20, $40 | Generic micronized prog. $25, $45 | Compounded cream $30, $50 | $75, $135 | | Mid-range | Brand patch (Vivelle-Dot) $45, $55 | Prometrium brand $55, $70 | Compounded cream $50, $80 | $150, $205 | | Branded/gel | EstroGel $60, $90 | Prometrium brand $55, $70 | Compounded cream $50, $80 | $165, $240 |

A woman using GoodRx or Mark Cuban's Cost Plus Drugs can often push the budget tier to the lower end. The generic estradiol patch plus generic micronized progesterone plus a compounded testosterone cream is realistically $75, $110 per month in most U.S. States.

Insurance Coverage: What to Expect

Estradiol patches and oral micronized progesterone are on most Tier 1 or Tier 2 formularies. With a standard commercial plan, a woman might pay $5, $25 per medication per month for these two drugs, dropping the insured cost to $10, $50 for the estrogen-progesterone pair alone.

Compounded testosterone is almost never covered by insurance and must be paid out of pocket regardless of plan type. This single item is the biggest differentiator between insured and uninsured costs.

Medicare Part B does not cover outpatient prescription drugs. Medicare Part D formularies include some estradiol and progesterone products, but coverage gaps and cost-sharing vary. Women on Medicare should check their specific plan's formulary at Medicare.gov before assuming coverage.

Telehealth Consultation Costs

The protocol requires a prescriber. In 2024, telehealth HRT platforms (including HealthRX) typically charge $75, $200 for an initial consultation and $50, $150 for quarterly follow-ups. A full year of care therefore adds $275, $650 to the annual medication cost, or roughly $23, $54 per month amortized.

For women who already have an ob-gyn who manages HRT, the incremental visit cost may be lower, though many primary care physicians do not feel comfortable prescribing testosterone off-label or managing compounded formulations.

The Evidence Base Behind Dr. Haver's Clinical Positions

Dr. Haver's public advocacy positions are not idiosyncratic. They track closely with guideline-level evidence from the Menopause Society and the Endocrine Society. Here is where the science stands on the key claims embedded in her stated regimen.

Hot Flashes and Bone: What Estrogen Does

Estradiol is the most effective pharmacological treatment for vasomotor symptoms. A Cochrane systematic review of 24 randomized controlled trials found that hormone therapy reduced hot flash frequency by approximately 75% compared with placebo. [6] For bone, estradiol is FDA-approved for the prevention of postmenopausal osteoporosis; data from the Women's Health Initiative showed that women randomized to combined HRT had 34% fewer hip fractures (hazard ratio 0.66, 95% CI 0.45 to 0.98) compared with placebo. [3]

Progesterone and Breast Safety

The breast cancer question is the most emotionally weighted aspect of HRT counseling. The absolute risk numbers matter. The Women's Health Initiative trial that used conjugated equine estrogen plus medroxyprogesterone acetate found 8 additional breast cancer cases per 10,000 women per year of use. [3] Estrogen-only therapy (for women without a uterus) was associated with a reduced breast cancer signal in the same trial. The substitution of micronized progesterone for medroxyprogesterone acetate is supported by the E3N cohort data above and by the 2022 Menopause Society Position Statement, which notes that micronized progesterone "appears to have a more favorable breast safety profile." [2]

Testosterone in Women: The Evidence Quality

Testosterone remains the most contested element. The 2019 Global Consensus Statement reviewed 36 randomized trials and found a statistically significant improvement in satisfying sexual events (standardized mean difference 0.31, P<0.001) with testosterone versus placebo in postmenopausal women. [4] Effects on mood, energy, and cognition are suggested by smaller trials but have not yet been established in large RCTs. Dr. Haver's framing of testosterone as beneficial for cognitive and mood symptoms is consistent with mechanistic plausibility and with her clinical experience, but falls into the "promising, not yet definitive" evidence tier.

Compounding vs. FDA-Approved Products: A Clinical Note

Because no FDA-approved testosterone product exists for women, compounding is effectively the only pathway in the United States. The FDA's oversight of compounding pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act requires that compounded products be made from USP-grade ingredients and prepared according to good compounding practices. [7]

Quality control is the practical concern. A 2020 study in Menopause (N=59 compounded testosterone products from 12 pharmacies) found significant variability in testosterone content, ranging from 67% to 133% of labeled concentration. [8] Women using compounded testosterone should have total serum testosterone checked at the 6 to 12 week mark to confirm absorption and avoid supraphysiologic levels, which can cause acne, clitoral enlargement, and voice changes.

Dr. Haver has publicly recommended monitoring serum testosterone, SHBG, and free testosterone levels in women using the hormone. This aligns with the 2019 Global Consensus Statement recommendation for annual monitoring. [4]

Who Qualifies for This Protocol? Candidate Selection

Not every symptomatic woman is a candidate for the full three-drug HRT protocol. The 2022 Menopause Society Position Statement and the Endocrine Society Clinical Practice Guideline on menopause both identify women who should avoid or use caution with systemic HRT. [2][4]

Standard Contraindications to Systemic Estrogen

• Personal history of estrogen-receptor-positive breast cancer
• Active or recent venous thromboembolism (deep vein thrombosis or pulmonary embolism)
• Active cardiovascular disease or recent coronary event
• Unexplained vaginal bleeding
• Active liver disease with impaired hepatic function

Women with these conditions may still be candidates for vaginal (local) estradiol for genitourinary symptoms, which carries minimal systemic absorption and no demonstrated increase in systemic risk. [2]

The Timing Window

The 2022 Menopause Society Position Statement is explicit: "For women who are under age 60 or within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome hot flashes and for prevention of bone loss." [2] Women who initiate HRT after age 60 or more than 10 years post-menopause face a less favorable risk-benefit profile, particularly for cardiovascular events and dementia risk.

Practical Steps to Access This Protocol Without a Celebrity Budget

Access does not require an expensive concierge physician or a boutique clinic. A structured pathway exists for most women.

Step 1: Confirm Menopause Status

For women over 45 with 12 consecutive months of amenorrhea, clinical diagnosis suffices. For younger women or those with irregular cycles, serum FSH above 40 mIU/mL on two measurements taken at least 4 weeks apart is diagnostic. [2]

Step 2: Baseline Labs

Before initiating HRT, a reasonable baseline includes: complete metabolic panel, fasting lipids, TSH (thyroid disorder mimics menopause), estradiol, FSH, and total testosterone with SHBG. Cost at a cash-pay lab (e.g., Labcorp patient portal or Quest) runs $80, $180 for the full panel. Insurance typically covers this if ordered by a clinician.

Step 3: Choose a Prescriber Pathway

Three options exist at different price points:

1. Ob-gyn or internal medicine physician who manages menopause. Covered under insurance for most women; requires a scheduled office visit.
2. Telehealth menopause specialist platform (e.g., HealthRX, Midi Health, Alloy). Initial visit $75, $200; prescriptions sent to a local pharmacy or compounding pharmacy.
3. Concierge or functional medicine clinic. Membership fees $200, $600/month. No clinical evidence these clinics produce better outcomes; cost is substantially higher.

Step 4: Follow-Up and Dose Titration

The standard follow-up interval after initiating HRT is 6 to 12 weeks for symptom check and, if testosterone is included, serum level confirmation. Annual mammography and endometrial safety monitoring (symptom-based rather than routine ultrasound in asymptomatic women on continuous combined HRT) apply thereafter. [2]

Does Dr. Haver's Publicly Described Regimen Differ From Standard of Care?

No. This is the key clinical point that her platform often obscures through sheer volume of content. The three-component protocol she describes (transdermal estradiol, micronized progesterone, low-dose testosterone) is what most menopause-specialist ob-gyns prescribe for symptomatic perimenopausal and postmenopausal women without contraindications. The Menopause Society's 2022 Position Statement, the Endocrine Society's guidelines, and the British Menopause Society's guidance all support this approach. [2][4]

What Dr. Haver has done is not invent a new protocol. She has communicated an existing evidence-based regimen to an audience that was largely unaware it existed. The access gap she addresses is real: a 2022 survey published in Menopause found that only 12% of U.S. Ob-gyn residents reported receiving formal menopause medicine training of more than 4 hours. [9] That training deficit translates directly into under-prescribing and undertreated patients.

Frequently Asked Questions